Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?

被引：0

作者：

Moreno-Ramirez, D. ^{[1
]}

Ferrandiz, L. ^{[1
]}

Fernandez-Orland, A. ^{[1
]}

机构：

[1] Hosp Univ Virgen Macarena, Serv Dermatol Med Quirurg & Venereol, Unidad Melanoma, Seville, Spain

来源：

ACTAS DERMO-SIFILIOGRAFICAS | 2024年 / 115卷 / 01期

关键词：

Melanoma; Immunotherapy; Targeted therapy; BRAF inhibitors; BRAF-MEK inhibitors; Adjuvant treatment; PD1; inhibitors; CTLA4; Neoadjuvant therapy; IMMUNE CHECKPOINT INHIBITORS; DABRAFENIB PLUS TRAMETINIB; COMBINED NIVOLUMAB; ADVERSE EVENTS; STAGE-III; IPILIMUMAB; ADJUVANT; PEMBROLIZUMAB; MULTICENTER; EFFICACY;

D O I：

10.1016/j.ad.2023.05.023

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Systemic treatment with immunotherapy or targeted therapy can significantly improve survival in patients with advanced (metastatic or high-risk) melanoma. Fifty percent of patients with melanoma have a BRAF mutation. Decisions on optimal sequencing of systemic treatments should take into account drug-and tumor-related factors and patient characteristics. Although the combination of ipilimumab and nivolumab is associated with the best survival outcomes, it is associated with significant toxicity. Targeted therapy may be a more favorable option in certain clinical situations. We review the literature on immunotherapy and targeted therapy in melanoma and present an algorithm for guiding decision-making on their use as first-line systemic treatments for advanced BRAF-mutated melanoma. (c) 2023 AEDV. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

引用

页码：48 / 55

页数：8

共 35 条

[1] The role of BRAF V600 mutation in melanoma [J].

Ascierto, Paolo A. ;

Kirkwood, John M. ;

Grob, Jean-Jacques ;

Simeone, Ester ;

Grimaldi, Antonio M. ;

Maio, Michele ;

Palmieri, Giuseppe ;

Testori, Alessandro ;

Marincola, Francesco M. ;

Mozzillo, Nicola .

JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10

[2] Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial [J].

Ascierto, Paolo A. A. ;

Mandala, Mario ;

Ferrucci, Pier Francesso ;

Guidoboni, Massimo ;

Rutkowski, Piotr ;

Ferraresi, Virginia ;

Arance, Ana ;

Guida, Michele ;

Maiello, Evaristo ;

Gogas, Helen ;

Richtig, Erika ;

Fierro, Maria Teresa ;

Lebbe, Celeste ;

Helgadottir, Hildur ;

Queirolo, Paola ;

Spagnolo, Francesco ;

Tucci, Marco ;

Del Vecchio, Michele ;

Gonzales Cao, Maria ;

Minisini, Alessandro Marco ;

De Placido, Sabino ;

Sanmamed, Miguel F. F. ;

Mallardo, Domenico ;

Curvietto, Marcello ;

Melero, Ignacio ;

Palmieri, Giuseppe ;

Grimaldi, Antonio M. ;

Giannarelli, Diana ;

Dummer, Reinhard ;

Sileni, Vanna Chiarion .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) :212-+

[3] Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134 [J].

Atkins, Michael B. ;

Lee, Sandra J. ;

Chmielowski, Bartosz ;

Tarhini, Ahmad A. ;

Cohen, Gary I. ;

Truong, Thach-Giao ;

Moon, Helen H. ;

Davar, Diwakar ;

O'Rourke, Mark ;

Stephenson, Joseph J. ;

Curti, Brendan D. ;

Urba, Walter J. ;

Brell, Joanna M. ;

Funchain, Pauline ;

Kendra, Kari L. ;

Ikeguchi, Alexandra P. ;

Jaslowski, Anthony ;

Bane, Charles L. ;

Taylor, Mark A. ;

Bajaj, Madhuri ;

Conry, Robert M. ;

Ellis, Robert J. ;

Logan, Theodore F. ;

Laudi, Noel ;

Sosman, Jeffrey A. ;

Crockett, David G. ;

Pecora, Andrew L. ;

Okazaki, Ian J. ;

Reganti, Sowjanya ;

Chandra, Sunandana ;

Guild, Samantha ;

Chen, Helen X. ;

Streicher, Howard Z. ;

Wolchok, Jedd D. ;

Ribas, Antoni ;

Kirkwood, John M. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) :186-+

[4] Patient performance status and cancer immunotherapy efficacy: a meta-analysis [J].

Bersanelli, Melissa ;

Brighenti, Matteo ;

Buti, Sebastiano ;

Barni, Sandro ;

Petrelli, Fausto .

MEDICAL ONCOLOGY, 2018, 35 (10)

[5] Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders [J].

Brown, Lauren J. ;

Weppler, Alison ;

Bhave, Prachi ;

Allayous, Clara ;

Patrinely, J. Randall, Jr. ;

Ott, Patrick ;

Sandhu, Shahneen ;

Haydon, Andrew ;

Lebbe, Celeste ;

Johnson, Douglas B. ;

Long, Georgina V. ;

Menzies, Alexander A. ;

Carlino, Matteo S. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (05)

[6] Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study [J].

Carroll, Robert P. ;

Boyer, Michael ;

Gebski, Val ;

Hockley, Bronwyn ;

Johnston, Julie K. ;

Kireta, Svjetlana ;

Tan, Hsiang ;

Taylor, Anne ;

Wyburn, Kate ;

RZalcberg, John .

LANCET ONCOLOGY, 2022, 23 (08) :1078-1086

[7] Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden [J].

Chalmers, Zachary R. ;

Connelly, Caitlin F. ;

Fabrizio, David ;

Gay, Laurie ;

Ali, Siraj M. ;

Ennis, Riley ;

Schrock, Alexa ;

Campbell, Brittany ;

Shlien, Adam ;

Chmielecki, Juliann ;

Huang, Franklin ;

He, Yuting ;

Sun, James ;

Tabori, Uri ;

Kennedy, Mark ;

Lieber, Daniel S. ;

Roels, Steven ;

White, Jared ;

Otto, Geoffrey A. ;

Ross, Jeffrey S. ;

Garraway, Levi ;

Miller, Vincent A. ;

Stephens, Phillip J. ;

Frampton, Garrett M. .

GENOME MEDICINE, 2017, 9

[8] DRUG DISCOVERY Inhibitors that activate [J].

Cichowski, Karen ;

Jaenne, Pasi A. .

NATURE, 2010, 464 (7287) :358-359

[9] Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study [J].

Cortellini, Alessio ;

Buti, Sebastiano ;

Santini, Daniele ;

Perrone, Fabiana ;

Giusti, Raffaele ;

Tiseo, Marcello ;

Bersanelli, Melissa ;

Michiara, Maria ;

Grassadonia, Antonino ;

Brocco, Davide ;

Tinari, Nicola ;

De Tursi, Michele ;

Zoratto, Federica ;

Veltri, Enzo ;

Marconcini, Riccardo ;

Malorgio, Francesco ;

Garufi, Carlo ;

Russano, Marco ;

Anesi, Cecilia ;

Zeppola, Tea ;

Filetti, Marco ;

Marchetti, Paolo ;

Botticelli, Andrea ;

Antonini Cappellini, Gian Carlo ;

De Galitiis, Federica ;

Vitale, Maria Giuseppa ;

Sabbatini, Roberto ;

Bracarda, Sergio ;

Berardi, Rossana ;

Rinaldi, Silvia ;

Tudini, Marianna ;

Silva, Rosa Rita ;

Pireddu, Annagrazia ;

Atzori, Francesco ;

Chiari, Rita ;

Ricciuti, Biagio ;

Iacono, Daniela ;

Migliorino, Maria Rita ;

Rossi, Antonio ;

Porzio, Giampiero ;

Cannita, Katia ;

Ciciarelli, Valeria ;

Fargnoli, Maria Concetta ;

Ascierto, Paolo Antonio ;

Ficorella, Corrado .

ONCOLOGIST, 2019, 24 (06) :E327-E337

[10] Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial [J].

Davies, Michael A. ;

Saiag, Philippe ;

Robert, Caroline ;

Grob, Jean-Jacques ;

Flaherty, Keith T. ;

Arance, Ana ;

Chiarion-Sileni, Vanna ;

Thomas, Luc ;

Lesimple, Thierry ;

Mortier, Laurent ;

Moschos, Stergios J. ;

Hogg, David ;

Marquez-Rodas, Ivan ;

Del Vecchio, Michele ;

Lebbe, Celeste ;

Meyer, Nicolas ;

Zhang, Ying ;

Huang, Yingjie ;

Mookerjee, Bijoyesh ;

Long, Georgina V. .

LANCET ONCOLOGY, 2017, 18 (07) :863-873

← 1 2 3 4 →